Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
Authors' conclusion
In RCTs, ICI use was associated with six CV irAEs, not confined to myocarditis and pericarditis.
Study context
- Population
- Cancer patients in randomized clinical trials (RCTs) with at least one ICI-containing arm and cardiovascular (CV) adverse event data
- Participants
- 32,518 patients · 63 RCTs
- Comparison
- ICI vs controls
- Outcome
- Summary risk of 16 different CVAEs associated with ICI exposure vs controls
Methodological detailsrandom-effects
- Random-effects
Pooled result
As reported in the abstract
CV irAEs (CVAEs with increased risk with ICI)
ICI vs ControlsPeto OR (95% CI)P value
Myocarditis; I2 = 0%, P = 0.93
4.42(1.56–12.50)
P < 0.01Dyslipidemia; I2 = 0%, P = 0.66
3.68(1.89–7.19)
P < 0.01Further pooled results
Summary incidence of CV immune-related adverse events (irAEs) · median follow-up 3.2 to 32.8 months
- Incidence range, lowest (per 1000 patients)
- 3.2 (95% CI 2.0-5.1)
- Incidence range, highest (per 1000 patients)
- 19.3 (6.7-54.1)
Original publication
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. Published 16 September 2021. doi:10.
Summarised from the published abstract; every number is checked against it